Table 2.
Risk Factors for De novo DSA
| Univariate | Multivariate (#1) | Multivariate (#2) | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| OR (CI) | P-value | OR (CI) | P-value | OR (CI) | P-value | |
|
| ||||||
| Age | ||||||
| 18–30 | 2.0(0.9–4.5) | P=0.12 | ||||
| >30–40 | 1.6(0.7–3.5) | P=0.24 | ||||
| >40–50 | 0.8(0.4–1.8) | P=0.85 | ||||
| >50–60 | 1.3(0.7–2.3) | P=0.43 | ||||
| >60 | 0.5(0.3–1.0) | P=0.04 | 0.7((0.3 – 1.4) | P=0.31 | ||
|
| ||||||
| Induction | ||||||
| Thymoglobulin | 1.0(0.6–1.7) | P=1.0 | ||||
| Basiliximab | 0.5(0.2–1.0) | P=0.05 | ||||
| Alemtuzumab | 2.1(1.1–3.8) | P=0.03 | 1.5(0.7–2.9) | P=0.26 | ||
|
| ||||||
| HLA mismatch (≥1) | ||||||
| A | 4.5(1.6–12.5) | P<0.01 | 2.5(0.82–9.5) | P=0.14 | ||
| B | 2.2(0.9–5.6) | P=0.10 | ||||
| DR | 3.2(1.3–8.1) | P<0.01 | 1.5(0.5––5.2) | P=0.48 | 4.8(2.0–14.3) | P<0.01 |
| DQ | 4.6(1.8–11.7) | P<0.01 | 3.5(1.4–10.7) | P=0.01 | ||
|
| ||||||
| HLA mismatch | NA | 1.1(1.3–0.9) per mismatch | P=0.42 | |||
|
| ||||||
| Acute cellular rejection* | 2.9(1.6–5.2) | P<0.01 | 2.6(1.3–5.1) | p=<0.01 | 2.4(1.3–4.5) | P<0.01 |
|
| ||||||
| Documented medication nonadherence | 7.5(3.9–14.2) | P<0.01 | 6.4(3.1–13.3) | P<0.01 | 7.9(3.9–15.4) | P<0.01 |
*
Prior to de novo DSA formation